Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene
about
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaLight microscopic detection of BCR-ABL transcripts after in-cell RT-PCR: fusion gene expression might correlate with clinical evolution of chronic myeloid leukemia.BCR/ABL transcripts and leukemia phenotype: an unsolved puzzle.BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients.Cytogenetics and molecular genetics of childhood leukemia.Models of chronic myeloid leukemia.Modeling Philadelphia chromosome positive leukemias.Philadelphia chromosome-positive acute myeloid leukemia with tetraploidy.A requirement for NF-kappaB activation in Bcr-Abl-mediated transformationThe P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivoNiche WNT5A regulates the actin cytoskeleton during regeneration of hematopoietic stem cellsMouse models as tools to understand and study BCR-ABL1 diseases.Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.Inhibition of P210 expression in chronic myeloid leukaemia: oligonucleotides and/or transduced antisense sequences.Disease progression in a murine model of bcr/abl leukemogenesis.Animal models of BCR/ABL-induced leukemias.Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.T-lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy: a report of 14 cases.
P2860
Q27025242-C44CF601-B942-4B63-91E8-F28A03D92677Q30839100-4132041D-7396-41CD-BF40-06D28A4C7AA0Q33368284-39128512-79C5-4DFD-B573-9787854EF164Q33508296-C933EB55-685D-4D74-9A6A-0B7B37F23AD1Q33820790-68D841E6-1838-4864-9AF5-1118DF52A5AEQ34214855-2CEFA89F-0A46-4208-B4DD-101165F38672Q34405446-E3600C23-62B2-4712-A310-1F3186EF072BQ34529622-AEAD331E-9ABB-4C34-A180-74325CBDDF55Q35195588-F7DD441E-36E9-4EF9-A45A-C7C92A6912E3Q36368162-451294B2-6646-4449-85EC-8ACC457ACA58Q36653547-88C54F26-2D8A-4611-9220-E7CA840F0554Q36965464-1046A6D2-3C88-4CCF-8398-99597198A09EQ37372835-4E43B3CF-2149-42F6-AF8A-CBA873D78FC2Q37549702-E39E78BE-8056-4F4B-B3F8-6211EB860F86Q37995194-BC6678A9-524B-4F82-9068-AB463967B9E8Q40722950-8BA5D870-6C1A-4788-80AC-2B1C785A8107Q40785905-F80894AF-9503-4661-A27C-33D5842A5A68Q40785957-7E356244-766E-4E18-9215-F2D9420574FAQ40785985-BB179ACF-326F-4881-A6DA-81ABFF42A3C6Q41971118-76B8EBD7-942C-4EF3-BD10-7CBD26361336Q48214714-16C53FFC-D21C-407A-B729-A3D928B6B6A1
P2860
Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Differences in oncogenic poten ...... forms of the BCR/ABL oncogene
@ast
Differences in oncogenic poten ...... forms of the BCR/ABL oncogene
@en
type
label
Differences in oncogenic poten ...... forms of the BCR/ABL oncogene
@ast
Differences in oncogenic poten ...... forms of the BCR/ABL oncogene
@en
prefLabel
Differences in oncogenic poten ...... forms of the BCR/ABL oncogene
@ast
Differences in oncogenic poten ...... forms of the BCR/ABL oncogene
@en
P2093
P2860
P356
P1476
Differences in oncogenic poten ...... forms of the BCR/ABL oncogene
@en
P2093
J McLaughlin
M Kelliher
N Rosenberg
P2860
P304
P356
10.1128/MCB.11.9.4710
P407
P577
1991-09-01T00:00:00Z